Multispecific NK engager protein

Patent metadata

Field	Value
Publication number	US-11267897-B2
Application number	US-201816173114-A
Country	US
Kind code	B2
Filing date	Oct 29, 2018
Priority date	Jun 23, 2015
Publication date	Mar 8, 2022
Grant date	Mar 8, 2022

Abstract

Multispecific proteins that bind and specifically redirect NK cells to lyse a target cell of interest are provided without non-specific activation of NK cells in absence of target cells. The proteins have utility in the treatment of disease, notably cancer or infectious disease.

First claim

The invention claimed is:

1. A multispecific antigen binding protein which promotes the specific lysis of target cells expressing an antigen of interest, which antigen is specifically bound by a therapeutic antibody or therapeutic antigen-binding antibody fragment, wherein said multispecific antigen binding protein comprises:
(i) a first antigen binding domain (ABD) which monovalently binds to a human NKp46 polypeptide having the amino acid sequence set forth in SEQ ID NO:1,
(ii) a second ABD which comprises a therapeutic antibody or a therapeutic antigen-binding antibody fragment which binds to said antigen of interest expressed by said target cells, and
(iii) a CD16A binding polypeptide,

wherein:
(1) said NKp46-binding ABD comprises a Fab or comprises a variable heavy (V H ) domain and a variable light (V L ) domain separated by a linker (“scFv”);
(2) said antigen-binding ABD which comprises said therapeutic antibody or therapeutic antigen-binding antibody fragment is monovalent or bivalent;
(3) said CD16A binding polypeptide comprises a human dimeric Fc domain polypeptide which binds CD16A;
(4) said multispecific antigen binding protein binds to the NKp46 polypeptide monovalently;
(5) said multispecific antigen binding protein when administered to a subject directs NKp46-expressing natural killer (NK) cells and CD16A-expressing NK cells to lyse target cells expressing the antigen of interest by a combination of NKp46-mediated signaling and CD16A-mediated antibody-dependent cell-mediated cytotoxicity (“ADCC”);
(6) said dimeric Fc domain interposes said first ABD and said second ABD; and
(7) said first and second ABD are each connected to said dimeric Fc domain, and one or both of said first and second ABD are connected to the dimeric Fc domain via a flexible polypeptide linker.

2. The multispecific antigen binding protein of claim 1 , wherein the therapeutic antibody specifically binds to an antigen expressed by cancer cells.

3. The multispecific antigen binding protein of claim 1 , wherein the therapeutic antigen-binding ABD comprises a Fab or comprises a V H domain and a V L domain separated by a linker comprising a linear or cyclic peptide.

4. The multispecific antigen binding protein of claim 1 , wherein the NKp46-binding ABD comprises a Fab.

5. The multispecific antigen binding protein of claim 1 , wherein the administration of said multispecific antigen binding protein to a subject increases the expression of CD137 on the surface of NK cells in said subject.

6. The multispecific antigen binding protein of claim 1 , wherein the NKp46-binding ABD is a Fab comprised of a V H domain and a V L domain, wherein each of the V H and V L domains is fused to a human C H1 or C κ constant domain.

7. The multispecific antigen binding protein of claim 1 , wherein the NKp46-binding ABD is a Fab comprised of (a) a V H domain fused to a human C H1 constant domain and a V L domain fused to a human C κ constant domain, or (b) a V H domain fused to a human C κ constant domain and a V L domain fused to a human C H1 constant domain.

8. The multispecific antigen binding protein of claim 1 , wherein the therapeutic antigen-binding ABD is a Fab comprised of a V H domain and a V L domain, wherein each of the V H and V L domains is fused to a human C H1 or C κ constant domain.

9. The multispecific antigen binding protein of claim 1 , wherein the therapeutic antigen-binding ABD is a Fab comprised of (a) a V H domain fused to a human C H1 constant domain and a V L domain fused to a human C κ constant domain, or (b) a V H domain fused to a human C κ constant domain and a V L domain fused to a human C H1 constant domain.

10. The multispecific antigen binding protein of claim 1 , wherein either or both the NKp46-binding ABD or the therapeutic antigen-binding ABD is bound to the Fc domain by a flexible polypeptide linker.

11. The multispecific antigen binding protein of claim 1 , wherein the monovalent NKp46 ABD comprises V H and V L domain polypeptides selected from the group consisting of:
(a) the V H and V L domains of SEQ ID NOS: 3 and 4 (NKp46-1);
(b) the V H and V L domains of SEQ ID NOS: 5 and 6 (NKp46-2);
(c) the V H and V L domains of SEQ ID NOS: 7 and 8 (NKp46-3);
(d) the V H and V L domains of SEQ ID NOS: 9 and 10 (NKp46-4);
(e) the V H and V L domains of SEQ ID NOS: 11 and 12 (NKp46-6); and
(f) the V H and V L domains of SEQ ID NOS: 13 and 14 (NKp46-9).

12. The multispecific antigen binding protein of claim 1 , wherein said flexible polypeptide linker is 2-50 amino acids in length.

13. The multispecific antigen binding protein of claim 1 , wherein one of the ABDs is connected to the Fc region via a peptide linker which comprises a hinge domain.

14. The multispecific antigen binding protein of claim 8 , wherein the C K constant domain and the human C H1 constant domain are each connected to the Fc domain via a hinge domain.

15. The multispecific antigen binding protein of claim 9 , wherein the C K constant domain and the human C H1 constant domain are each connected to the Fc domain via a hinge domain.

16. The multispecific antigen binding protein of claim 1 , wherein said combination of NKp46-mediated signaling and CD16A-mediated ADCC has an additive or synergistic effect on the lysis of target cells expressing the antigen of interest.

17. The multispecific antigen binding protein of claim 2 , wherein the therapeutic antigen-binding ABD binds to an antigen expressed by hematological cancer cells.

18. The multispecific antigen binding protein of claim 17 , wherein the antigen expressed by said hematological cancer cells comprises CD19 or CD20.

19. A pharmaceutical composition comprising a pharmaceutically effective amount of the multispecific antigen binding protein of claim 1 .

Assignees

• Innate Pharma

Inventors

• Gauthier Laurent
• Anceriz Nadia
• Morel Ariane
• Rossi Benjamin

Classifications

• C07K16/2866 Primary

  against receptors for cytokines, lymphokines, interferons · CPC title

• A61K40/4211

  CD19 or B4 · CPC title

• A61K40/15

  Natural-killer [NK] cells; Natural-killer T [NKT] cells · CPC title

• A61K2239/48

  Blood cells, e.g. leukemia or lymphoma · CPC title

• C07K2317/31

  multispecific · CPC title